Steinberg Asset Management LLC trimmed its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 53.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 7,493 shares of the company’s stock after selling 8,633 shares during the quarter. Steinberg Asset Management LLC’s holdings in Henry Schein were worth $629,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Operose Advisors LLC purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $33,000. Trust Co. of Vermont bought a new stake in shares of Henry Schein during the second quarter valued at approximately $42,000. Root Financial Partners LLC bought a new stake in shares of Henry Schein during the third quarter valued at approximately $50,000. Versant Capital Management Inc increased its position in shares of Henry Schein by 175.4% during the second quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock valued at $52,000 after acquiring an additional 393 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Henry Schein by 167.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock worth $69,000 after acquiring an additional 586 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.
Henry Schein Price Performance
HSIC opened at $84.88 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a 50 day moving average price of $86.53 and a 200-day moving average price of $81.09. Henry Schein, Inc. has a twelve month low of $62.44 and a twelve month high of $92.18. The stock has a market capitalization of $9.46 billion, a price-to-earnings ratio of 24.75, a PEG ratio of 1.53 and a beta of 0.84.
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same quarter last year, the company posted $1.10 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 5.36 earnings per share for the current year.
Analysts Set New Price Targets
HSIC has been the topic of several analyst reports. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. Stifel Nicolaus set a $95.00 target price on Henry Schein in a report on Wednesday, August 5th. UBS Group set a $94.00 price target on Henry Schein and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. BTIG Research boosted their price target on Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Finally, Citigroup reaffirmed a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.27.
Get Our Latest Stock Analysis on HSIC
Henry Schein Company Profile
Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.
In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.
Read More
- Five stocks we like better than Henry Schein
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
